Skip to main content
. Author manuscript; available in PMC: 2013 May 15.
Published in final edited form as: Pharmacogenet Genomics. 2010 Feb;20(2):86–93. doi: 10.1097/FPC.0b013e32833428d0

Fig. 2.

Fig. 2

Receiver operating characteristic (ROC) curves of Clinical and Combined Clinical and Pharmacogenetic Predictive Tests. The middle lines correspond to the Clinical Predictive Test and the top lines correspond to the Combined Clinical and Pharmacogenetic Predictive Test. The bottom lines represent an area under the ROC (AUROC) of 0.50 which would represent a test that has no discriminatory value. (a) Childhood Asthma Management Program (CAMP). The AUROC is 0.55 for the Clinical Predictive Test and is significantly better at 0.65 for the Pharmacogenetic Predictive Test, P=0.038. (b) Effectiveness of Low-Dose Theophylline as Add-on Treatment in Asthma Trial. The AUROC is 0.44 for the Clinical Predictive Test and is significantly better at 0.63 for the Pharmacogenetic Predictive Test, P=0.0037. (c) Asthma Trial conducted by Sepracor. The AUROC is 0.52 for the Clinical Predictive Test and is significantly better at 0.61 for the Pharmacogenetic Predictive Test, P=0.033.